Akebia Therapeutics announced that the Swiss Agency for Therapeutic Products has granted marketing authorization for Vafseo, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease in adults on chronic maintenance dialysis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKBA: